Trisenox and blood bilirubin increased Patient Reports February 13, 2012

Trisenox Side Effects Report #5325380-4
Trisenox side effect was reported by a Physician from JAPAN on Apr 26, 2007. Female patient, 73 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: altered state of consciousness, blood bilirubin increased, cerebral haemorrhage, condition aggravated, dialysis , disseminated intravascular coagulation, hyperglycaemia, leukocytosis, pulmonary haemorrhage. Trisenox dosage: 7.62 MG QD INTRAVENOUS DRIP. During the same period patient was treated with ETOPOSIDE, TEICOPLANIN, NAFAMOSTAT MESILATE, MICONAZOLE, HYDROCORTISONE SUCCINATE, FAMOTIDINE. Patient died on 11/09/2005.

Trisenox Side Effects Report #5680028-4
Trisenox side effect was reported by a Physician from JAPAN on Mar 12, 2008. Male patient, 63 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, acute promyelocytic leukaemia, alanine aminotransferase increased, aspartate aminotransferase increased, blood albumin decreased, blood alkaline phosphatase increased, blood bilirubin increased, blood calcium decreased, blood lactate dehydrogenase increased. Trisenox dosage: K9.75 MG QD; INTRAVENOUS. During the same period patient was treated with ARBEKACIN SULPHATE, MEROPENEM, MEXILETINE HYDROCHLORIDE, DALTEPARIN, HYDROCORTISONE SUCCINATE, RANITIDINE HYDROCHLORIDE, ALLOPURINOL. Patient was hospitalized. Patient died on 05/10/2007.

Trisenox Side Effects Report #5701452-7
Trisenox side effect was reported by a Physician from JAPAN on Mar 24, 2008. Male patient, 63 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, acute promyelocytic leukaemia, alanine aminotransferase increased, aspartate aminotransferase increased, blood albumin decreased, blood alkaline phosphatase increased, blood bilirubin increased, blood calcium decreased, blood creatinine increased. Trisenox dosage: 9.75 MG, QD; INTRAVENOUS. During the same period patient was treated with ARBEKACIN SULPHATE, MEROPENEM TRIHYDRATE, MEROPENEM TRIHYDRATE, MEXILETINE HYDROCHLORIDE, DALTEPARIN, HYDROCORTISONE SUCCINATE, RANITIDINE HYDROCHLORIDE. Patient was hospitalized. Patient died on 05/08/2007.

Trisenox Side Effects Report #5757804-2
Trisenox side effect was reported by a Physician from FRANCE on May 15, 2008. Female patient, 59 years of age, weighting 130.1 lb, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: abscess , alanine aminotransferase increased, aplasia, aspartate aminotransferase increased, blood bilirubin increased, blood chloride decreased, blood potassium decreased, blood pressure diastolic decreased, blood sodium decreased. Trisenox dosage: 9 MG DAILY 5 DAYS EVERY 7 DAYS FOR 35 DAYS INTRAVENOUS. During the same period patient was treated with ZOVIRAX, TAZOCILLINE, TARGOCID, IDARUBICIN, CYTARABINE. Patient was hospitalized. Patient died on 04/13/2008.


Trisenox Side Effects Report #5768566-7
Trisenox side effect was reported by a Physician from FRANCE on May 29, 2008. Female patient, 59 years of age, weighting 130.1 lb, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: aspartate aminotransferase increased, blood bilirubin increased, blood chloride decreased, blood potassium decreased, blood pressure diastolic decreased, blood sodium decreased, brain scan abnormal, bronchopulmonary aspergillosis, cerebral disorder. Trisenox dosage: 9 MG DAILY 5 DAYS EVERY 7 DAYS FOR 35 DAYS INTRAVENOUS. During the same period patient was treated with ZOVIRAX, TAZOCILLINE, TARGOCID, IDARUBICIN, CYTARABINE. Patient was hospitalized. Patient died on 04/13/2008.

Trisenox Side Effects Report #5125019-7
Trisenox side effect was reported by a Physician from JAPAN on Sept 22, 2006. Male patient, 58 years of age, weighting 132.3 lb, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, blood bilirubin increased, cerebral haemorrhage, condition aggravated, disseminated intravascular coagulation, hepatic function abnormal, hypercalcaemia, hyperglycaemia, hyponatraemia. Trisenox dosage: 9 MG QD INTRAVENOUS DRIP. During the same period patient was treated with GABEXATE MESILATE, DANAPAROID, FUROSEMIDE, VORICONAZOLE, SULFAMETHOXAZOLE. Patient was hospitalized. Patient died on 05/16/2006.

Trisenox Side Effects Report #5179504-2
Trisenox side effect was reported by a Physician from JAPAN on Nov 30, 2006. Male patient, 58 years of age, weighting 132.3 lb, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, blood bilirubin increased, cerebral haemorrhage, condition aggravated, disseminated intravascular coagulation, febrile neutropenia, fungal infection , hepatic function abnormal, hypercalcaemia. Trisenox dosage: 9 MG QD INTRAVENOUS DRIP. During the same period patient was treated with GABEXATE MESILATE, DANAPAROID, FUROSEMIDE, VORICONAZOLE, SULFAMETHOXAZOLE W. Patient was hospitalized. Patient died on 05/16/2006.

Trisenox Side Effects Report #5718737-0
Trisenox side effect was reported by a Physician from JAPAN on Apr 10, 2008. Female patient, 58 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: acute promyelocytic leukaemia differentiation syndrome, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, blood lactate dehydrogenase increased, blood potassium decreased, blood urea increased, electrocardiogram qt prolonged, gamma-glutamyltransferase increased. Trisenox dosage: 8.85 MG QD INTRAVENOUS DRIP. During the same period patient was treated with IDARUBICIN, POTASSIUM SUPPLEMENT, GABEXATE MESILATE, CARPERITIDE, MICAFUNGIN. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #5266132-3
Trisenox side effect was reported by a Physician from JAPAN on Feb 27, 2007. Female patient, 57 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: acute promyelocytic leukaemia differentiation syndrome, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood lactate dehydrogenase increased, c-reactive protein increased, condition aggravated, disseminated intravascular coagulation. Trisenox dosage: unknown. During the same period patient was treated with CYTARABINE, IDARUBICIN, DANAPAROID, CARBAZOCHROME SULFONATE, TRANEXAMIC ACID, MONOAMMONIUM GLYCYRRHIZINATE. Patient died on 12/31/2006.


Trisenox Side Effects Report #5320867-2
Trisenox side effect was reported by a Physician from JAPAN on Apr 24, 2007. Female patient, 57 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, electrocardiogram qt prolonged, hepatic function abnormal, herpes zoster, white blood cell count decreased. Trisenox dosage: 8.475 MG QD INTRAVENOUS DRIP. During the same period patient was treated with RANITIDINE HYDROCHLORIDE, ALLOPURINOL, PRAVASTATIN, SULFAMETHOXAZOLE AND TRIMETHOPRIM, BROTIZOLAM, ETIZOLAM. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #4801211-3
Trisenox side effect was reported by a Physician from JAPAN on Sept 26, 2005. Female patient, 36 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: bacterial infection , blood bilirubin increased, c-reactive protein increased, electrocardiogram qt corrected interval prolonged, electrocardiogram qt prolonged, jaundice , neutrophil count decreased, pyrexia, white blood cell count decreased. Trisenox dosage: 6.93 MG QD INTRAVENOUS DRIP. During the same period patient was treated with LACTOBACILLUS CASEI, LENOGRASTIM, CEFCAPENE PIVOXIL, GENTAMICIN, BUFEXAMAC. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #6025811-0
Trisenox side effect was reported by a Physician from UNITED STATES on Dec 08, 2008. Male patient, 63 years of age, weighting 218.9 lb, was diagnosed with acute myeloid leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood bilirubin increased, hypotension, neutropenic sepsis, respiratory distress. Trisenox dosage: 24 MG QD INTRAVENOUS. During the same period patient was treated with CYTARABINE. Patient was hospitalized. Patient recovered.

Trisenox Side Effects Report #6032601-1
Trisenox side effect was reported by a Physician from UNITED STATES on Dec 23, 2008. Male patient, 63 years of age, weighting 218.9 lb, was diagnosed with acute myeloid leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood bilirubin increased, cardio-respiratory arrest, neutropenic sepsis, septic shock. Trisenox dosage: 24 MG QD INTRAVENOUS. During the same period patient was treated with CYTARABINE. Patient was hospitalized. Patient died on 12/20/2008.

Trisenox Side Effects Report #6139392-4
Trisenox side effect was reported by a Physician from UNITED STATES on Mar 13, 2009. Male patient, 63 years of age, weighting 218.9 lb, was diagnosed with acute myeloid leukaemia and was treated with Trisenox. After drug was administered, patient experienced the following side effects: blood bilirubin increased, cardio-respiratory arrest, hypotension, increased bronchial secretion, increased upper airway secretion, mucosal inflammation, neutropenic sepsis, respiratory distress, septic shock. Trisenox dosage: 24 MG (24 MG, 1 IN 1 D), INTRAVENOUS. During the same period patient was treated with CYTARABINE. Patient was hospitalized. Patient died on 12/20/2008.